Cover Page

Universiteit Leiden

Leiden University Repository

The handle http://hdl.handle.net/1887/20397 holds various files of this Leiden University dissertation.

Author: Anninga, Jakob Klaas
Title: Clinical and molecular features of high-grade osteosarcoma
Issue Date: 2013-01-09

8

Summary and concluding remarks

Chapter 8

In this thesis 7 chapters are presented, describing clinical, pathological and molecular studies related to the most common primary bone tumour, osteosarcoma. **Chapter 1**, the **general introduction**, is an overview of epidemiology including incidence, age distribution, localization in the skeleton, risk factors and survival. The objective of this description is to gain more insight in the clinico-pathological behavior of osteosarcoma, based on epidemiologic information (1). The *incidence* pattern is age dependent. Osteosarcoma in children under 5 years of *age* is rare, less than 2% of all osteosarcomas occur in this age group. A steep rise in incidence occurs during puberty, peaking at an incidence of 8.6 cases/10^6 population up to 20 years of age, followed by a low rate of on average 1.7/10^6 population during adulthood (25–59 years of age) (2). A non-unified second peak occurs in people of 60+ years, reaching 4.9/10^6 new cases yearly. Remarkably, this 2nd incidence peak is absent in the Asian people (3). This peak has suggested to be due to secondary osteosarcomas, after radiation or as complication of Paget's disease. The different distribution and histology of osteosarcomas in patients older than 60 years of age suggests indeed a distinctive biological behaviour. An adequate *treatment* is of utmost importance for survival of patients that has not improved the past 2-3 decades. Contemporary treatment consists of pre-and postoperative (neo-adjuvant) chemotherapy and radical surgery. If no clear resection margins can be obtained, the patient has a very high risk of being incurable.

With respect to the *prognosis* of patients with osteosarcoma, the chances for survival after incomplete surgery are less than 15% (4). Hence locations where complete resection is impossible, for example axial or pelvic site, have strong influence on outcome. Axial site is more often present in older patients, therefore age can be biased by the site of the primary tumour with respect to prognosis. For resectable disease, metastases at diagnosis, proximal site and large (≥ 1/3 extremity length) size of the primary tumour are the most important adverse prognostic factors (4-6). Two treatment related factors are also of favourable prognostic importance, these are good histologic response on pre-operative chemotherapy and presence of chemotherapy induced toxicity (7). Other factors, such as pathological fracture at diagnosis, type of surgery, age and gender were of minor prognostic importance. Genetic risk factors, like the Li-Fraumeni syndrome, the (heritable or bilateral) Retinoblastoma, the helicase-mutation syndromes and other diseases in their context to osteosarcoma are discussed in this chapter. The *pathology* of osteosarcoma was discussed, with emphasis on the unconventional subtypes of high-grade osteosarcoma and the low-grade osteosarcoma variants. This was chosen because these variants contribute to only 5% of all osteosarcomas but, were overrepresented in the hands and feet (discussed in chapter 6).

In **chapter 2** the literature of chemotherapeutic treatment of localized, non-metastatic osteosarcoma of the extremities was reviewed. One of the main conclusions was that there are not more than 4 effective cytostatic drugs, where efficacy is defined as an response rate (RR) in phase-II trials of 20% or more. These 4 drugs are doxorubicin (RR 43%), ifosfamide (RR 33%), methotrexate (RR 32%) and cisplatin (RR 26%). Meta-analysis demonstrated that 2-drug regimens (mainly consisting of doxorubicin and cisplatin) are inferior to regimens containing 3 or more drugs. According to this analysis there was no survival benefit of 4-drug regimens compared to 3-drug regimens. Therefore a 3-drug combination such as

methotrexate, doxorubicin (a.k.a. adriamycine) and cisplatin, a regimen referred to as MAP, is considered the best induction regimen and should be used as standard treatment for osteosarcoma in clinical protocols. The debate remains whether adding a high responsive drug, like ifosfamide, to MAP should be reserved for non-responding patients or in cases of progressive disease. Furthermore, it was concluded that investigating more of this type of conventional drug regimens would not be advantageous.

Therefore, we started a study in osteosarcomas to investigate if genome wide gene expression provides a better insight into the biology of this tumour. Gene expression pattern of 25 high-grade osteosarcoma biopsies were correlated to the outcome of disease or response to neo-adjuvant treatment. In addition we investigated if drug targets from such expression data could be determined. The results of this study were presented in **chapter 3** and showed that nearly 3000 genes were significantly differentially expressed in osteosarcoma, compared with non-malignant cells (osteoblastomas, mesenchymal stem cells and mesenchymal stem cells differentiated into osteoblasts). Gene expression profiles could not be correlated to either response to treatment or survival. Analysis at a single gene level proved to be not useful in osteosarcomas, because this tumour has a highly complex karyotype, that diminishes the reliability of single genes to predict the clinical determinants of malignant diseases, unless thousands of samples are used (8). Therefore, pathway analysis was chosen as a method for further analysis of malignant transformation of the mesenchymal stem cell, the presumed precursor of osteosarcoma (9).

At pathway level, we found down-regulation of the Wnt3a/β-catenin signalling (reflected by downregulation of Axin and CCND1), upregulation of the Wnt5a/alternative signalling, overexpression of the cell cycle genes and a disturbed p53/apoptotic pathway (reflected by downregulation of BBC3/PUMA) in osteosarcomas.

The statistical background for the choice for pathways analysis is described in chapter 4. This paper describes the algorithm for the association of the expression of groups of genes with clinical variables. The groups of genes can be clustered based on pathways, as defined for example in the Gene Ontology data base (http://amigo.geneontology.org) (10). The Global Test can test the statistical significance of a certain pathway, attributed to a clinical variable of interest, for instance survival. The test is based on the Cox proportional hazards model, with the possibility to adjust for the presence of co-variables. In this paper, the expression profile of the patients, whose biopsies were analyzed in chapter 3, were tested. Using this model it was found that pathways, involving the cell cycle, DNA repair and apoptosis were associated with survival. It was further concluded that using the Cox model, survival data are not lost and can be adjusted for the presence of co-variates, which allows to improved performance of this test.

In order to establish molecular targets for osteosarcoma treatment, the epidermal growth factor receptor HER2 was mentioned as a candidate and is the subject of research, described in **chapter 5**. Her2 is highly expressed in 25% of the breast cancer patients, and its related tumorigenic effects (11, 12) can be reverted by the monoclonal antibody trastuzumab (Herceptin®) (13). Based on the presumed overexpression of Her2 in osteosarcomas (14-16), a phase-II study with trastuzumab was initiated in osteosarcomas (www.cancer.gov/clinical trials: MSKCC-99097/NCI-T98-0083 and COG-AOST0121). However, in our study no

membranous (3+) HER2 overexpression was found, which is a prerequisite for tratstuzumab treatment (17, 18). Neither HER2 mRNA was overexpressed at the gene level, nor FISH analysis showed *HER2*-gene amplification in the single sample that stained moderate (2+) positive membrane staining. We concluded that *HER2*-gene amplification or membranous HER2 protein overexpression is absent in human osteosarcoma, and that we cannot support the principle to treat osteosarcomas with Herceptin.

After we had confirmed the complexity of osteosarcoma at molecular level with the gene-expression study, another question was whether there is also clinical evidence for heterogeneity of osteosarcomas. To answer this question, we studied the clinico-pathological features of osteosarcomas with a rare localization, i.e. the small tubular and flat bones of the hands and feet. The results of this study are described in **chapter 6.** In total 40 patients with osteosarcomas of the hands or feet, obtained from the merged Dutch (10/1733) and the Rizzoli Institutional databases (30/2488) were described, representing only 0.95% of all osteosarcomas, present in both databases. Compared with the usual sites (around the knee or humerus), osteosarcomas in hands or feet occurred in older patients (mean age 42 years), with a male predominance (male female ratio=1.7:1), patients had a longer delay before the definitive diagnoses was made, and had a higher proportion of low grade (30%) and intermediate grade (5%) of malignancy compared to osteosarcoma at conventional sites, that show low-grade malignancy in 1%–2% (19). Overall cumulative incidence of death (CID) of the whole group was 80%, however worse in patients with location in the hands (4y CID 38%) than in the feet (2.5 CID 11%), and no deaths were observed in patients with low–or intermediate grade osteosarcomas. It was concluded that high-grade osteosarcoma of the hands or feet are a peculiar subgroup of osteosarcomas, and that high-grade tumours have a similar prognosis as osteosarcoma in the long tubular bones of the skeleton. It is recommended to treat high-grade osteosarcomas of the distal extremities in the same way as those tumours at conventional sites.

The last part of this thesis, **chapter 7**, deals with osteosarcoma as systemic disease, which occurs as synchronous metastases (metastases at diagnosis, in 16% of the newly diagnosed patients (4, 20-24) or as recurrent or relapsed disease (metachronous metastases), which occurs in 45% of all patients treated for localized osteosarcoma (4, 20-26). A study was done to determine prognostic factors in 88 patients with pulmonary (n=26 synchronic, n=62 metachronic) metastases from the Leiden University Medical Center data base. Overall survival of the patients with resectable metastatic osteosarcoma was 23%, not worse for patients with synchronous versus metachronous metastases. Survival was determined only by resectability of the metastases, even if surgery was more often than once required. Poor prognostic factors for survival in patients who underwent surgery were high (5 or more) number of metastases (HR 1.29), whereas favorable prognostic factors were necrotic metastases (HR 0.17) and female gender (HR 0.41). Although it would suggest that pre–operative chemotherapy could induce necrotic metastases, the trend towards better survival for patients who received chemotherapy, found in this study was not significant (χ^2 p=0.04). Overall, it was concluded that cure can be achieved in a subset of patients with (synchronous or metachronous) metastases by aggressive surgical treatment, but the role of chemotherapy remains elusive.

DISCUSSION

From the above chapters it can be concluded that high-grade osteosarcoma cannot be considered as one disease, but is a heterogeneous tumour at clinical, pathological and genomic level. This may be the reason that contributes to the lack of improvement in survival during the past 3 decades. One of the important findings in this thesis was that there are only 4 effective drugs against high-grade osteosarcoma, i.e. doxorubicin, methotrexate, cisplatin and ifosfamide. After relapse, the treatment options become even more limited, because re-using the same drugs questions their efficacy, and adds to the cumulative toxicity of these drugs (27), like cardiac (28), hearing loss (29), renal damage (30, 31), fertility problems (32, 33) or second malignancies (34). Treatment with the monoclonal antibody Herceptin could not be supported by us and others, because there is no membranous HER2-receptor overexpression on osteosarcomas, as is shown by us and others (35-38). Array analysis revealed up-regulation of cell cycle genes and a disturbed Wnt- and p53/apoptotic signalling as most important abnormal pathways in osteosarcomas compared with non-malignant cells. Upregulation of cell cycle genes is not surprising in cancer cells, neither disturbance of the apoptotic pathway. In order to think of the Wnt-signalling as potential therapeutic target for osteosarcoma, the Wnt-pathway in general and as far relevant for osteosarcoma will shortly be discussed shortly in the next paragraph.

Wnt-pathway

The Wnt signalling plays an important role in developmental biology and in cancer (39, 40). Due to the numerous Wnt-ligands (n=19), Wnt-receptors (Frizzled: Fzd's n=10), co-receptors (n=8) and modulators, like Wnt-inhibitors (Dickkopfs, Wnt-inhibiting factors, soluble Fzd-related proteins and proteoglycans) the downstream signals after ligand-receptor binding are pleiotropic and tissue specific, spatial-and time dependent (39, 41, 42). That means that the effect of Wnt signalling in the bone marrow niche (reservoir mesenchymal stem cells (MSC) is different from Wnt signalling in cartilage of tubular bones or in flat bones, or in other tissues. For an extensive discussion about these topics, the reader is referred to some excellent reviews (39, 40, 43, 44).

Modern insights in these complexities have replaced the old distinction of canonical and non-canonical by β-catenin dependent and β-catenin independent respectively, and an overview of both pathways is given in Figure 1. In summary, the β-*catenin dependent (or canonical)* pathway stabilizes cytoplasmatic β-catenin after binding of the Wnt3a (or other "canonical" Wnts) with the Fzd2/7 receptor, by inhibiting the proteosomal degradation of the continuously formed β-catenin (Fig.1 A) (40). Due to the rising cytoplasmatic concentration, β-catenin shuttles to the nucleus, and activates transcription factors for proliferation (de-repression) (45) or induces differentiation (co-activation) of for instance Runx2 (46, 47), a master gene for osteogenesis. The β-catenin independent signalling is activated after binding of Wnt5a with either Fzd2 (Fig.1, B) or Fzd4 (Fig.1 C), with or without the co-receptor ROR2 or with ROR2 as a single receptor (Fig.1 E). The oncogenic transcription factor Jun-N-terminal kinase (JNK)

(48) is activated after Wnt5a–Fzd2 binding mediated by the small GTP–ases Rho and Rac (Fig.1 C), and is called the *Wnt/PCP pathway* (41, 49). The other ß-catenin independent signalling, the *Wnt/Ca²⁺ pathway* (Fig.1 D), activates the transcription factors NEMO or NFAT, which inhibit ß-catenin dependent proliferation (50, 51) and activate osteogenesis (52, 53) respectively. Other modulations of the Wnt5a signalling are shown in Fig.1 by the red circles and are at the level of competitive inhibition of Wnt3a binding with Fzd receptors (Fig.1 F), via the ubiquitin ligase Siah2 (54, 55) or directly via ROR2 activation (56).

Bone development is an complex process, in which Wnt's play an important role in multiple ways (see Fig.2) (for reviews, see (44, 47, 57)). In the early MSC stage Wnt3a/β-catenin is required for lineage fate decision (57-59) and stimulates the proliferation of stem cells to maintain an adequate number of progenitor cells. Furthermore, Wnt3a signalling prevents osteo-chondrogenic progenitors from developing into cartilage and differentiate into osteoblasts (46, 60, 61), but for the definitive differentiation into the osteogenic lineage, Wnt3a needs temporary be downregulated (62, 63), which is mediated via Wnt5a and Dkk1 (62-64). Finally, the β-catenin pathway is required for definitive differentiation of precursor cells into osteocytes (63, 65).

FIGURE 1.
Wnt signalling pathways.

This figure shows a number of different Wnt-signalling pathways, as well as possible cross-talks between the β-catenin dependent ("canonical", column A), and β-catenin independent ("non-canonical", column B-E) pathways. The Wnt3a-activated ("on") β-catenin dependent pathway under column A and the β-catenin repressive ("off") situation in column F. See text for details. The β-catenin independent signalling is divided into the Wnt/PCP/Jnk and Wnt/Ca2+ pathways. Recently, insights have added a Wnt-Ror2 pathway has been added to these pathways, which inhibits the canonical pathway at 4 possible levels. Firstly, by competitive inhibition with the Wnt3a receptor binding (Red circle 1), by increased degradation of β-catenin via ROR-2 activated Siah-2 activity (red circle 2), by repression of TCF3 transcription via NEMO (red circle 3), or by directly inhibition of β-catenin–TCF binding (red circle 4). Another cross-talk is β-catenin activation, when Wnt5a binds to the Frizzled4 (Fzd4) receptor. The different and complex outcomes of the various Wnt signalling pathways are the result of binding of "canonical" (represented by Wnt3a) or "non-canonical" (represented by Wnt5a) Wnt-ligands to multiple receptors (Fzd's), either with or without different co-receptors (Lrp's, ROR's or Ryk's), modulated by inhibitors, such as the Dickkopf's (Dkk's), the Wnt-inhibiting factors (WIF's), the soluble Frizzled related proteins (sFRP's), or Sclerostin (SOST). LRP5,6 lipoprotein related protein 5,6; Dvl Dishevelled; APC Adenomatous Polyposis Coli; GSK–3β Glycogen Synthase Kinase–3β; CK1 Casein Kinase–1α; CamKII Calcium/Calmoduline dependent Kinase II; JNK c-Jun N-terminal Kinase; Rock2 Rho-associated Kinase; β-TrCP is a ubiquitin ligase; TCF1/3 T-cell factor 1/3; Lef1 Lymphoid Enhancer Factor 1; Gro Groucho.

FIGURE 2.
Wnt-signaling in stages of osteoblastic development.

The two Wnt-signalling pathways are represented by Wnt3a as *Wnt3a/β-catenin dependent* and Wnt5a as *Wnt/β-catenin independent pathways*. The orange and purple line at the bottom of figure 2 are the hypothetical levels of each of the Wnt-pathways, showing a inhibition of the β-catenin pathway, by Wnt5a and probably Dkk1. In the early mesenchymal stem cell (MSC) stage, β-catenin stimulates the proliferative activity of the cell, and induces the MSC to the osteo-chondrogenic lineage, thereby suppressing the adipogenic lineage (ASC = adipogenic stem cell). In a later stage of the osteochodrogenic progenitor cell, Wnt3a stimulates proliferation of the progenitor cells to ensure a pool of these cells, inhibits chondrogenic differentiation (by suppressing SOX9 and IHH) and starts the induction of the osteogenesis by activating the transcriptionfactor Runx2. To continue osteoblastogenesis, Wnt3a needs to be downregulated, which is done by Wnt5a, and probably Dkk1. For the terminal differentiation of the osteoblasts into osteocytes, Wnt3a has to be upregulated again, in order to activate transcription factors is necessary for differentiation to osteocytes. Disruption of this tightly regulated signalling in normal bone development leads to hyperproliferation, defective differentiation commitment control, resulting in genetic instability and osteosarcomagenesis.

In normal osteogenesis, other signalling systems, such as bone morphogenetic proteins (BMP) and Hedgehog (IHH) are required but are not further discussed here.

Wnt-signalling, cancer and osteosarcoma

In our array study we found evidence for down-regulation of the Wnt3a/β-catenin pathway and up-regulation of the alternative, Wnt5a pathway. This is in contrast to the activating β-catenin deregulation, which is the driving force for tumourgenesis in most types of epithelial cancers, for example in colon cancer (66), ovarian cancer (67), prostate cancer (68) or lung cancer (69). Wnt3a/β-catenin overexpression has been reported in osteosarcoma, either directly (70, 71) or indirectly by inhibition of the Wnt ligand (72, 73) or due to overexpression of the co-receptor LRP5 (74). However, overexpression of β-catenin, as seen in the Gardner syndrome, did not result in an increased incidence of osteosarcomas (75), whereas in the benign osteoblastomas clear expression of β-catenin was observed (76).

Absent nuclear β-catenin staining was observed in only one other study of osteosarcoma (77). Recently, Mathushansky reported that inactivation of the β-catenin dependent Wnt pathway was tumorigenic in the high-grade undifferentiated pleomorphic sarcoma (78). It was shown that the mesenchymal stem cell was the progenitor of the undifferentiated sarcoma and that down-regulation of the Wnt/β-catenin dependent pathway failed to commit the stem cell to differentiation into mature connective tissue lineages. In addition Wnt5a was defective in regulating a commitment-viability checkpoint, as is known that this non-canonical pathway mediates anti-apoptotic signalling (79). In another study the Wnt/β-catenin signalling was downregulated in Rhabdomyosarcoma cell line, blocking the normal myogenic differentiation and increasing resistance to apoptosis (80). Restoration of the Wnt3a activation resulted in myogenic differentiation.

Another example of the contribution of an inactive Wnt3a/β-catenin signalling is reported in Retinoblastoma's (81). Wnt signalling re-activation significantly decreased the viability of the retinoblastoma cells by p53-induced cell cycle arrest. The authors concluded that the Wnt-pathway acted as a tumour suppressor in the retinoblastoma cells lines, and that loss of Wnt signalling contributed to the tumorigenesis in the retina.

Inactivity of the Wnt3a/β-catenin signalling in our study has been confirmed by Cai et al. (76). Restoration of the Wnt3a/β-catenin pathway by inhibition of GSK-3β, that phosphorylates β-catenin, demonstrated differentiation into bone of 2 of 4 osteosarcoma cell lines.

What exactly the role of the downregulation of the Wnt3a/β-catenin pathway in the tumorgenesis of osteosarcoma is, remains difficult to explain. The hypothesis is that, similar as in undifferentiated sarcomas and rhabdomyosarcomas, bone-progenitor cells will not be able to complete osteogenesis and remain in continuous proliferative state (as was shown by the upregulated cell cycle genes). The overexpressed Wnt5a signalling on the other hand drives the osteo-progenitor cells into the direction of osteogenesis (82). However, due to the disturbed apoptotic regulation these cells lack a differentiation commitment check, that results in progressive genomic instability, which is the hallmark of osteosarcoma (83, 84). However, this is still hypothesis, and it would be a challenge to study Wnt-signalling in the normal osteogenesis and in the disturbed osteogenesis, such as in osteosarcoma, or in other pathologic conditions.

Wnt signalling and potential therapies

Given the observations that the Wnt3a/β-catenin pathway was inactive in osteosarcomas and that 2 of 4 osteosarcoma cell lines differentiated into normal bone after inhibition of GSK3β, it could be argued that therapy, aiming to inhibit proteosomal degradation of β-catenin might be of advantage in patients with the Wnt-pathway in the off-state. One of the most promising compounds to interfere with the proteosomal activity is bortezomib (85, 86). This drug has shown to restore normal bone development in Multiple Myeloma patients (87, 88), irrespective the response on treatment (89). Although the mechanism is not completely resolved, it has been suggested in these patients that bortezomib inhibits the Wnt3a antagonist Dkk1 (87), induced differentiation of osteoblasts via stabilization of β-catenin (86), or via bortezomib induced apoptosis of the tumour cells (90). In mice that were treated with bortezomib, inhibition of cell proliferation and increased apoptosis of the osteosarcoma cells was obsesrved, resulting in regression of the tumour (85). Bortezomib has been used in clinical phase-1 (91), phase-II (92) or phase-III studies (93), is tolerated well with few side effects. Even in combination with other drugs, that might be used in (refractory) osteosarcoma, or in older patients, bortezomib can be used safely (94-96). Therefore, bortezomib might one of the few agents worth for future evaluation in osteosarcoma therapy, preferably in a window phase in patients with absent Wnt3a/β-catenin dependent signalling.

CONCLUDING REMARKS

It can be concluded from this thesis that high-grade osteosarcoma is at clinical, pathological and molecular level a heterogeneous disease. To treat high-grade osteosarcoma adequately, neo-adjuvant chemotherapy should be combined with radical surgery, irrespective the localization of the tumour. An adequate chemotherapy regimen for osteosarcoma consists at least of 3 out of 4 effective cytostatic agents, i.e. methotrexate, doxorubicin and cis-platin. A fourth active agent, ifosfamide, should possibly be reserved for patients with refractory disease or patients with relapse. Patients with metastatic pulmonary osteosarcoma should receive surgery in case of resectable disease, whereas the use of chemotherapy is these patients can be considered, but is not of proven value. Patients with irresectable metastatic osteosarcoma should be offered phase-I and phase-II studies, because no response can be expected from other conventional cytostatic drug combinations. With respect to new drug developments, the use of the monoclonal antibody trastuzumab against HER2 is not supported by us, because we were not able to demonstrate overexpression of the HER2 receptor on osteosarcoma cells. At molecular level, a disturbed Wnt signalling was found in addition to abnormal cell cycle regulation and a disturbed p53/apoptotic pathway. This combination of these pathway abnormalities might be oncogenic. Failure of the mesenchymal stem cell to differentiate into the osteoblastic lineage, due to abnormal proliferation and lack of differentiation commitment results in chromosomal instability, which is the hallmark of osteosarcoma. In patients with an inactive Wnt3a/β-catenin signalling the proteasome inhibitor bortezomib might be a candidate drug, to explore its suggested differentiation inducing properties. More research should be directed to study Wnt signalling in normal and disturbed osteogenesis, in order to clarify the mechanisms by which Wnt3a has its effects in osteosarcoma.

REFERENCES

1. Savage SA, Mirabello L: Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma 2011:548151, 2011

2. Mirabello L, Troisi RJ, Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531-1543, 2009

3. Mirabello L, Troisi RJ, Savage SA: International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 125:229-234, 2009

4. Bielack SS, Kempf-Bielack B, Delling G, et al.: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776-790, 2002

5. Bacci G, Longhi A, Versari M, et al.: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106:1154-1161, 2006

6. Whelan JS, Jinks RC, McTiernan A, et al.: Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann Oncol, 2011

7. McTiernan A, Jinks RC, Sydes MR, et al.: Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. Eur J Cancer 48:703-712, 2012

8. Ein-Dor L, Zuk O, Domany E: Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A 103:5923-5928, 2006

9. Mohseny AB, Szuhai K, Romeo S, et al.: Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 219:294-305, 2009

10. Goeman JJ, van de Geer SA, de KF, et al.: A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 20:93-99, 2004

11. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001

12. Park JW, Neve RM, Szollosi J, et al.: Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 8:392-401, 2008

13. Drebin JA, Link VC, Stern DF, et al.: Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:697-706, 1985

14. Onda M, Matsuda S, Higaki S, et al.: ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77:71-78, 1996

15. Gorlick R, Huvos AG, Heller G, et al.: Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17:2781-2788, 1999

16. Akatsuka T, Wada T, Kokai Y, et al.: ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94:1397-1404, 2002

17. Baselga J: Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 61 Suppl 2:14-21, 2001

18. Wolff AC, Hammond ME, Schwartz JN, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007

19. Inwards CY, Knuutila S: Low grade central osteosarcoma, in Fletcher CDM, Unni KK, Mertens F (eds): Pathology and genetics of tumours of soft tissue and bone. Lyon, IARC Press, 2002, pp 275-276

20. Petrilli AS, de CB, Filho VO, et al.: Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol 24:1161-1168, 2006

21. Le Deley MC, Guinebretiere JM, Gentet JC, et al.: SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 43:752-761, 2007

22. Wu PK, Chen WM, Chen CF, et al.: Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients. Jpn J Clin Oncol 39:514-522, 2009

23. Picci P, Mercuri M, Ferrari S, et al.: Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol 21:1366-1373, 2010

24. Janeway KA, Barkauskas DA, Krailo MD, et al.: Outcome for adolescent and young adult patients with osteosarcoma: A report from the Children's Oncology Group. Cancer, 2012

25. Munoz A, Alfaro J, Pardo N, et al.: Long-term results of the Spanish Protocol SO-95 for the treatment of non-metastatic high-grade osteosarcoma of the extremities in children. Clin Transl Oncol 11:387-392, 2009

26. Gelderblom H, Jinks RC, Sydes M, et al.: Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer 47:895-902, 2011

27. Janeway KA, Grier HE: Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol 11:670-678, 2010

28. Longhi A, Ferrari S, Bacci G, et al.: Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs 18:737-744, 2007

29. Bertolini P, Lassalle M, Mercier G, et al.: Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26:649-655, 2004

30. Stohr W, Paulides M, Bielack S, et al.: Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer 48:140-147, 2007

31. Stohr W, Paulides M, Bielack S, et al.: Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System. Pediatr Blood Cancer 48:447-452, 2007

32. Wallace WH, Shalet SM, Crowne EC, et al.: Gonadal dysfunction due to cis-platinum. Med Pediatr Oncol 17:409-413, 1989

33. Longhi A, Macchiagodena M, Vitali G, et al.: Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol 25:292-296, 2003

34. Bacci G, Ferrari C, Longhi A, et al.: Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol 28:774-780, 2006

35. Thomas DG, Giordano TJ, Sanders D, et al.: Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 8:788-793, 2002

36. Somers GR, Ho M, Zielenska M, et al.: HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol 8:525-532, 2005

37. Willmore-Payne C, Holden JA, Zhou H, et al.: Evaluation of Her-2/neu gene status in osteosarcoma by fluorescence in situ hybridization and multiplex and monoplex polymerase chain reactions. Arch Pathol Lab Med 130:691-698, 2006

38. Baumhoer D, Smida J, Specht K, et al.: Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma. Hum Pathol 42:859-866, 2011

39. Kikuchi A, Yamamoto H, Sato A, et al.: New insights into the mechanism of Wnt signaling pathway activation. Int Rev Cell Mol Biol 291:21-71, 2011

40. Clevers H, Nusse R: Wnt/b-catenin signaling and disease. Cell 149:1192-1205, 2012

41. van AR, Nusse R: Towards an integrated view of Wnt signaling in development. Development 136:3205-3214, 2009

42. Verkaar F, Zaman GJ: A model for signaling specificity of Wnt/Frizzled combinations through co-receptor recruitment. FEBS Lett 584:3850-3854, 2010

43. Logan CY, Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781-810, 2004

44. Monroe DG, McGee-Lawrence ME, Oursler MJ, et al.: Update on Wnt signaling in bone cell biology and bone disease. Gene 492:1-18, 2012

45. Sokol SY: Maintaining embryonic stem cell pluripotency with Wnt signaling. Development 138:4341-4350, 2011

46. Day TF, Guo X, Garrett-Beal L, et al.: Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8:739-750, 2005

47. Hartmann C: A Wnt canon orchestrating osteoblastogenesis. Trends Cell Biol 16:151-158, 2006

48. Whitmarsh AJ, Davis RJ: Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene 26:3172-3184, 2007

49. Rao TP, Kuhl M: An updated overview on Wnt signaling pathways: a prelude for more. Circ Res 106:1798-1806, 2010

50. Topol L, Jiang X, Choi H, et al.: Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol 162:899-908, 2003

51. Zanotti S, Canalis E: Nemo-like kinase inhibits osteoblastogenesis by suppressing bone morphogenetic protein and WNT canonical signaling. J Cell Biochem 113:449-456, 2012

52. Koga T, Matsui Y, Asagiri M, et al.: NFAT and Osterix cooperatively regulate bone formation. Nat Med 11:880-885, 2005

53. Winslow MM, Pan M, Starbuck M, et al.: Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev Cell 10:771-782, 2006

54. Liu J, Stevens J, Rote CA, et al.: Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 7:927-936, 2001

55. Verkaar F, Zaman GJ: New avenues to target Wnt/beta-catenin signaling. Drug Discov Today 16:35-41, 2011

56. Billiard J, Way DS, Seestaller-Wehr LM, et al.: The orphan receptor tyrosine kinase Ror2 modulates canonical Wnt signaling in osteoblastic cells. Mol Endocrinol 19:90-101, 2005

57. Leucht P, Minear S, Ten BD, et al.: Translating insights from development into regenerative medicine: the function of Wnts in bone biology. Semin Cell Dev Biol 19:434-443, 2008

58. Li HX, Luo X, Liu RX, et al.: Roles of Wnt/beta-catenin signaling in adipogenic differentiation potential of adipose-derived mesenchymal stem cells. Mol Cell Endocrinol 291:116-124, 2008

59. Gambardella A, Nagaraju CK, O'Shea PJ, et al.: Glycogen synthase kinase-3alpha/beta inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage. J Bone Miner Res 26:811-821, 2011

60. Hill TP, Spater D, Taketo MM, et al.: Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 8:727-738, 2005

61. Grigoryan T, Wend P, Klaus A, et al.: Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev 22:2308-2341, 2008

62. Boland GM, Perkins G, Hall DJ, et al.: Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 93:1210-1230, 2004

63. Marcellini S, Henriquez JP, Bertin A: Control of osteogenesis by the canonical Wnt and BMP pathways in vivo: Cooperation and antagonism between the canonical Wnt and BMP pathways as cells differentiate from osteochondroprogenitors to osteoblasts and osteocytes. Bioessays, 2012

64. Zhang C, Cho K, Huang Y, et al.: Inhibition of Wnt signaling by the osteoblast-specific transcription factor Osterix. Proc Natl Acad Sci U S A 105:6936-6941, 2008

65. Yang F, Tang W, So S, et al.: Sclerostin is a direct target of osteoblast-specific transcription factor osterix. Biochem Biophys Res Commun 400:684-688, 2010

66. Holcombe RF, Marsh JL, Waterman ML, et al.: Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol Pathol 55:220-226, 2002

67. Barbolina MV, Burkhalter RJ, Stack MS: Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment. Biochem J 437:1-12, 2011

68. Wan X, Liu J, Lu JF, et al.: Activation of beta-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res 18:726-736, 2012

69. You L, He B, Xu Z, et al.: Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 23:6170-6174, 2004

70. Haydon RC, Deyrup A, Ishikawa A, et al.: Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 102:338-342, 2002

71. Vijayakumar S, Liu G, Rus IA, et al.: High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/beta-catenin target gene, CDC25A. Cancer Cell 19:601-612, 2011

72. Kansara M, Tsang M, Kodjabachian L, et al.: Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119:837-851, 2009

73. Rubin EM, Guo Y, Tu K, et al.: Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther 9:731-741, 2010

74. Hoang BH, Kubo T, Healey JH, et al.: Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 109:106-111, 2004

75. Bilkay U, Erdem O, Ozek C, et al.: Benign osteoma with Gardner syndrome: review of the literature and report of a case. J Craniofac Surg 15:506-509, 2004

76. Cai Y, Mohseny AB, Karperien M, et al.: Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol 220:24-33, 2010

77. Ng TL, Gown AM, Barry TS, et al.: Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 18:68-74, 2005

78. Matushansky I, Hernando E, Socci ND, et al.: Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 117:3248-3257, 2007

79. Almeida M, Han L, Bellido T, et al.: Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 280:41342-41351, 2005

80. Singh S, Vinson C, Gurley CM, et al.: Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice. Am J Pathol 177:2055-2066, 2010

81. Tell S, Yi H, Jockovich ME, et al.: The Wnt signaling pathway has tumor suppressor properties in retinoblastoma. Biochem Biophys Res Commun 349:261-269, 2006

82. Baksh D, Boland GM, Tuan RS: Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. J Cell Biochem 101:1109-1124, 2007

83. Al-Romaih K, Bayani J, Vorobyova J, et al.: Chromosomal instability in osteosarcoma and its association with centrosome abnormalities. Cancer Genet Cytogenet 144:91-99, 2003

84. Overholtzer M, Rao PH, Favis R, et al.: The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A 100:11547-11552, 2003

85. Shapovalov Y, Benavidez D, Zuch D, et al.: Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. Int J Cancer 127:67-76, 2010

86. Qiang YW, Hu B, Chen Y, et al.: Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 113:4319-4330, 2009

87. Oyajobi BO, Garrett IR, Gupta A, et al.: Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol 139:434-438, 2007

88. Qiang YW, Barlogie B, Rudikoff S, et al.: Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 42:669-680, 2008

89. Heider U, Kaiser M, Muller C, et al.: Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 77:233-238, 2006

90. Giuliani N, Morandi F, Tagliaferri S, et al.: The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110:334-338, 2007

91. Dy GK, Thomas JP, Wilding G, et al.: A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res 11:3410-3416, 2005

92. Ramalingam SS, Davies AM, Longmate J, et al.: Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol 6:1741-1745, 2011

93. Schwartz R, Davidson T: Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park) 18:14-21, 2004

94. Irvin WJ, Jr., Orlowski RZ, Chiu WK, et al.: Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clin Breast Cancer 10:465-470, 2010

95. Falchook GS, Duvic M, Hong DS, et al.: Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. Cancer Chemother Pharmacol 69:1117-1126, 2012

96. Fanale M, Fayad L, Pro B, et al.: Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol 154:284-286, 2011